EUVIMEDEUVIMED entdecken
Crossref

Risk-Based AQbD Framework for Development, Optimization and Validation of a Stability-Indicating RP-HPLC Method for Tapinarof: A Systematic Analytical Approach

Sayad Imran Wahab, Mirza Shahed Baig

International Journal of Drug Delivery Technology · 17.06.2026 · 16 (55s)

DOI: 10.25258/ijddt.16.55s.55 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 17.06.2026. Verfasst von Sayad Imran Wahab und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tapinarof, a first-in-class non-steroidal topical aryl hydrocarbon receptor (AhR) agonist approved by the USFDA for plaque psoriasis (2022) and atopic dermatitis (2025), lacks any Analytical Quality by Design (AQbD) based stabilityindicating RP-HPLC method in the published literature; this study addresses that gap by developing, optimizing and validating such a method for Tapinarof in bulk API and Tapinarof cream 1% w/w in compliance with ICH Q8(R2), Q9(R1), Q10, Q14, and Q2(R2). The AQbD workflow encompassed Analytical Target Profile (ATP), FMEA-based risk assessment identifying three Critical Method Parameters % acetonitrile, flow rate and column temperature and a 20 run Central Composite Design (CCD) for response surface optimization with Method Operable Design Region (MODR) establishment via Design Expert® overlay plots; forced degradation was performed under all six ICH Q1A(R2)/Q1B stress conditions and analyzed on a Shimadzu SPD-M40 PDA-HPLC system (Kromasil C18, 250 × 4.6 mm, 4 µm). The DoE-optimized isocratic method (ACN:0.05% OPA:MeOH, 55:35:10 v/v/v, pH 3.0; 1.0 mL/min; λ = 330 nm; 30°C; 15 min) yielded Rt = 7.854 min (T = 1.079; N = 8,449); CCD models achieved R² = 0.9784; photolytic stress (ICH Q1B) produced the maximum degradation (19.25%), generating a single resolved degradant DP-1 (Rt = 4.213 min; Rs = 3.82) validation demonstrated linearity R² = 0.9997 (10–150 µg/mL), accuracy 99.92–100.08%, precision % RSD ≤ 0.55%, LOD = 0.136 µg/mL, LOQ = 0.412 µg/mL, PDA peak purity confirmed. This first AQbD-optimized stability-indicating RP-HPLC method for Tapinarof was validated per ICH Q2 (R2).

Zitieren

APA

Wahab, S. I., & Baig, M. S. (2026). Risk-Based AQbD Framework for Development, Optimization and Validation of a Stability-Indicating RP-HPLC Method for Tapinarof: A Systematic Analytical Approach. International Journal of Drug Delivery Technology, 16(55s). https://doi.org/10.25258/ijddt.16.55s.55

Vancouver

Wahab SI, Baig MS. Risk-Based AQbD Framework for Development, Optimization and Validation of a Stability-Indicating RP-HPLC Method for Tapinarof: A Systematic Analytical Approach. International Journal of Drug Delivery Technology. 2026;16(55s). doi:10.25258/ijddt.16.55s.55

BibTeX
@article{Wahab2026,
  author = {Wahab, Sayad Imran and Baig, Mirza Shahed},
  title = {Risk-Based AQbD Framework for Development, Optimization and Validation of a Stability-Indicating RP-HPLC Method for Tapinarof: A Systematic Analytical Approach},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {55s},
  doi = {10.25258/ijddt.16.55s.55}
}
Kostenlos starten →